Trial Profile
A Phase 2 Trial of RAD001 in Low and Intermediate-1 Risk Myelodysplastic Syndrome.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 03 May 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 17 Nov 2011 Planned End Date changed from 1 Dec 2012 to 1 Feb 2009 as reported by ClinicalTrials.gov.
- 17 Nov 2011 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.